Envista (NYSE:NVST) Rating Increased to Outperform at Robert W. Baird

Robert W. Baird upgraded shares of Envista (NYSE:NVST - Free Report) from a neutral rating to an outperform rating in a research note released on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has $23.00 price objective on the stock, up from their previous price objective of $21.00.

Several other research analysts have also issued reports on NVST. Bank of America cut their target price on shares of Envista from $26.00 to $23.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Needham & Company LLC reissued a "hold" rating on shares of Envista in a research report on Thursday, March 6th. Morgan Stanley set a $16.00 target price on Envista in a research report on Tuesday, April 15th. New Street Research set a $19.00 price target on Envista in a research note on Thursday, March 6th. Finally, Wells Fargo & Company set a $19.00 price target on Envista in a report on Saturday, March 8th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $20.23.

Envista Trading Up 2.9%

Shares of NYSE:NVST traded up $0.52 during midday trading on Tuesday, reaching $18.52. The company's stock had a trading volume of 4,231,728 shares, compared to its average volume of 2,572,460. Envista has a fifty-two week low of $14.22 and a fifty-two week high of $23.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The firm has a 50 day moving average price of $16.62 and a two-hundred day moving average price of $18.78. The firm has a market capitalization of $3.14 billion, a price-to-earnings ratio of -2.85, a PEG ratio of 1.27 and a beta of 0.97.

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.04. The firm had revenue of $616.90 million for the quarter, compared to analyst estimates of $608.17 million. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. The company's revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.26 earnings per share. As a group, analysts forecast that Envista will post 1 earnings per share for the current year.

Institutional Investors Weigh In On Envista

Several institutional investors have recently bought and sold shares of NVST. Lecap Asset Management Ltd. bought a new position in Envista during the 4th quarter valued at $281,000. Hantz Financial Services Inc. raised its holdings in shares of Envista by 146.6% in the fourth quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company's stock valued at $2,131,000 after purchasing an additional 65,679 shares during the last quarter. Norges Bank bought a new position in shares of Envista during the fourth quarter valued at about $38,052,000. Natixis Advisors LLC lifted its position in shares of Envista by 1.8% during the fourth quarter. Natixis Advisors LLC now owns 106,652 shares of the company's stock valued at $2,057,000 after purchasing an additional 1,845 shares in the last quarter. Finally, Lightrock Netherlands B.V. purchased a new position in Envista during the fourth quarter worth about $5,193,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.